Jean-Mathieu Beauregard

List of Publications by Year
in descending order

54	1,450	304743	330143
papers	citations	22 h-index	37 g-index

56	56	56	1810
all docs	docs citations	times ranked	citing authors

#	Article	IF	Citations
1	The tumour sink effect on the biodistribution of 68Ga-DOTA-octreotate: implications for peptide receptor radionuclide therapy. European Journal of Nuclear Medicine and Molecular Imaging, 2012, 39, 50-56.	6.4	119
2	Quantitative 177 Lu SPECT (QSPECT) imaging using a commercially available SPECT/CT system. Cancer Imaging, 2011, 11, 56-66.	2.8	111
3	Personalized 177Lu-octreotate peptide receptor radionuclide therapy of neuroendocrine tumours: initial results from the P-PRRT trial. European Journal of Nuclear Medicine and Molecular Imaging, 2019, 46, 728-742.	6.4	109
4	⁶⁸Ga PET/CT Ventilationâ€“Perfusion Imaging for Pulmonary Embolism: A Pilot Study with Comparison to Conventional Scintigraphy. Journal of Nuclear Medicine, 2011, 52, 1513-1519.	5.0	87
5	Personalized 177Lu-octreotate peptide receptor radionuclide therapy of neuroendocrine tumours: a simulation study. European Journal of Nuclear Medicine and Molecular Imaging, 2017, 44, 1490-1500.	6.4	84
6	An automated voxelized dosimetry tool for radionuclide therapy based on serial quantitative SPECT/CT imaging. Medical Physics, 2013, 40, 112503.	3.0	66
7	ORIGINAL ARTICLE: Pilot comparison of ¹⁸Fâ€fluorocholine and ¹⁸Fâ€fluorodeoxyglucose PET/CT with conventional imaging in prostate cancer. Journal of Medical Imaging and Radiation Oncology, 2010, 54, 325-332.	1.8	56
8	Impact of Point Spread Function Reconstruction on Thoracic Lymph Node Staging With 18F-FDG PET/CT in Nonâ€“Small Cell Lung Cancer. Clinical Nuclear Medicine, 2012, 37, 971-976.	1.3	53
9	FDG-PET/CT for pre-operative staging and prognostic stratification of patients with high-grade prostate cancer at biopsy. Cancer Imaging, 2015, 15, 2.	2.8	47
10	Accuracy of 177Lu activity quantification in SPECT imaging: a phantom study. EJNMMI Physics, 2017, 4, 2.	2.7	46
11	Accuracy and reproducibility of simplified QSPECT dosimetry for personalized 177Lu-octreotate PRRT. EJNMMI Physics, 2018, 5, 25.	2.7	45
12	Clinical Utility of Amyloid PET Imaging in the Differential Diagnosis of Atypical Dementias and Its Impact on Caregivers. Journal of Alzheimer's Disease, 2016, 52, 1251-1262.	2.6	44
13	Potentiation of 177Lu-octreotate peptide receptor radionuclide therapy of human neuroendocrine tumor cells by PARP inhibitor. Oncotarget, 2018, 9, 24693-24706.	1.8	44
14	Determination of gamma camera calibration factors for quantitation of therapeutic radioisotopes. EJNMMI Physics, 2018, 5, 8.	2.7	37
15	Assessment of Human Biodistribution and Dosimetry of 4-Fluoro-11Î²-Methoxy-16Î±-¹⁸F-Fluoroestradiol Using Serial Whole-Body PET/CT. Journal of Nuclear Medicine, 2009, 50, 100-107.	5.0	36
16	GLUT1 expression in high-risk prostate cancer: correlation with 18F-FDG-PET/CT and clinical outcome. Prostate Cancer and Prostatic Diseases, 2020, 23, 441-448.	3.9	36
17	High throughput static and dynamic small animal imaging using clinical PET/CT: potential preclinical applications. European Journal of Nuclear Medicine and Molecular Imaging, 2010, 37, 991-1001.	6.4	34
18	PSMA Theranostics: Current Landscape and Future Outlook. Cancers, 2021, 13, 4023.	3.7	33

#	Article	IF	Citations
19	Rapid blood clearance and lack of long-term renal toxicity of 177Lu-DOTATATE enables shortening of renoprotective amino acid infusion. European Journal of Nuclear Medicine and Molecular Imaging, 2013, 40, 1853-1860.	6.4	32
20	Feasibility of single-time-point dosimetry for radiopharmaceutical therapies. Journal of Nuclear Medicine, 2021, 62, jnumed.120.254656.	5.0	28
21	Accuracy of kidney dosimetry performed using simplified time activity curve modelling methods: a ¹⁷⁷Lu-DOTATATE patient study. Physics in Medicine and Biology, 2019, 64, 175006.	3.0	26
22	Increased Prostate Cancer Glucose Metabolism Detected by 18F-fluorodeoxyglucose Positron Emission Tomography/Computed Tomography in Localised Gleason 8â€“10 Prostate Cancers Identifies Very Highâ€“risk Patients for Early Recurrence and Resistance to Castration. European Urology Focus, 2019, 5, 998-1006.	3.1	25
23	[18F]Fluorinated estradiol derivatives for oestrogen receptor imaging: impact of substituents, formulation and specific activity on the biodistribution in breast tumour-bearing mice. European Journal of Nuclear Medicine and Molecular Imaging, 2008, 35, 1473-1479.	6.4	22
24	Combination treatments to enhance peptide receptor radionuclide therapy of neuroendocrine tumours. European Journal of Nuclear Medicine and Molecular Imaging, 2020, 47, 907-921.	6.4	21
25	Comprehensive SPECT/CT system characterization and calibration for 177Lu quantitative SPECT (QSPECT) with dead-time correction. EJNMMI Physics, 2020, 7, 10.	2.7	18
26	Neuroradiological and Neuropathological Changes After 177Lu-Octreotate Peptide Receptor Radionuclide Therapy of Refractory Esthesioneuroblastoma. Operative Neurosurgery, 2018, 15, 100-109.	0.8	16
27	Metabolic Imaging of Prostate Cancer Reveals Intrapatient Intermetastasis Response Heterogeneity to Systemic Therapy. European Urology Focus, 2017, 3, 639-642.	3.1	15
28	Chemotherapy-Induced Upregulation of Somatostatin Receptor-2 Increases the Uptake and Efficacy of 177Lu-DOTA-Octreotate in Neuroendocrine Tumor Cells. Cancers, 2021, 13, 232.	3.7	15
29	Clinical Impact of a Second FDG-PET in Atypical/Unclear Dementia Syndromes. Journal of Alzheimer's Disease, 2015, 49, 695-705.	2.6	13
30	Early anterior cingulate involvement is seen in presymptomatic MAPT P301L mutation carriers. Alzheimer's Research and Therapy, 2021, 13, 42.	6.2	13
31	Role of Artificial Intelligence in Theranostics. PET Clinics, 2021, 16, 627-641.	3.0	12
32	Prostate-specific membrane antigen for prostate cancer theranostics: from imaging to targeted therapy. Current Opinion in Supportive and Palliative Care, 2018, 12, 359-365.	1.3	11
33	Impact of dead time on quantitative 177Lu-SPECT (QSPECT) and kidney dosimetry during PRRT. EJNMMI Physics, 2020, 7, 32.	2.7	11
34	Effective specific activities determined by scintillation proximity counting for production runs of [18F]FES and 4F-M[18F]FES. Nuclear Medicine and Biology, 2007, 34, 325-329.	0.6	10
35	Steroid Receptor Imaging in Breast Cancer. PET Clinics, 2006, 1, 51-70.	3.0	9
36	Personalized kidney dosimetry in ¹⁷⁷Lu-octreotate treatment of neuroendocrine tumours: a comparison of kidney dosimetry estimates based on a whole organ and small volume segmentations. Physics in Medicine and Biology, 2019, 64, 175004.	3.0	8

#	Article	IF	Citations
37	New developments in the imaging of metastatic prostate cancer. Current Opinion in Supportive and Palliative Care, 2014, 8, 265-270.	1.3	7
38	Posterior Cingulate Cortex Hypometabolism in Non-Amnestic Variants of Alzheimerâ€™s Disease. Journal of Alzheimer's Disease, 2020, 77, 1569-1577.	2.6	7
39	The Tripleâ€Tracer strategy against Metastatic PrOstate cancer (3TMPO) study protocol. BJU International, 2022, 130, 314-322.	2.5	6
40	A Dual Radiologic Contrast Agent Protocol for 18F-FDG and 18F-FLT PET/CT Imaging of Mice Bearing Abdominal Tumors. Molecular Imaging and Biology, 2011, 13, 518-525.	2.6	5
41	Evaluation of a new visual uptake scoring scale for 18F-fluorothymidine positron emission tomography in the diagnosis of pulmonary lesions. Nuclear Medicine Communications, 2013, 34, 521-526.	1.1	5
42	How we read FCH-PET/CT for prostate cancer. Cancer Imaging, 2016, 16, 41.	2.8	5
43	18F-Fluorodeoxyglucose positron emission tomography/computed tomography (PET/CT) is accurate for high-grade prostate cancer bone staging when compared to bone scintigraphy. Canadian Urological Association Journal, 2021, 15, 301-307.	0.6	5
44	Optimizing the Schedule of PARP Inhibitors in Combination with 177Lu-DOTATATE: A Dosimetry Rationale. Biomedicines, 2021, 9, 1570.	3.2	4
45	Reversal of Severe and Refractory Humoral Hypercalcemia With 177Lu-Octreotate Peptide Receptor Radionuclide Therapy for Neuroendocrine Tumor of the Pancreas. Clinical Nuclear Medicine, 2015, 40, e448-e450.	1.3	3
46	A CZT-based blood counter for quantitative molecular imaging. EJNMMI Physics, 2017, 4, 18.	2.7	3
47	Highly Symptomatic Progressing Cardiac Paraganglioma With Intracardiac Extension Treated With 177Lu-DOTATATE: A Case Report. Frontiers in Endocrinology, 2021, 12, 705271.	3.5	2
48	Quantitative SPECT (QSPECT) at high count rates with contemporary SPECT/CT systems. EJNMMI Physics, 2021, 8, 73.	2.7	2
49	Harmonization of nomenclature for molecular imaging metrics of tumour burden: molecular tumour volume (MTV), total lesion activity (TLA) and total lesion fraction (TLF). European Journal of Nuclear Medicine and Molecular Imaging, 2022, 49, 424-426.	6.4	2
50	Clinical Outcomes in Patients Treated with Selective HDR Image-Guided Boost to Dominant Intra-Prostatic Lesion. Brachytherapy, 2016, 15, S52.	0.5	1
51	Sci-Thur AM: YIS - 03: irtGPUMCD: a new GPU-calculated dosimetry code for 177 Lu-octreotate radionuclide therapy of neuroendocrine tumors. Medical Physics, 2014, 41, 1-1.	3.0	1
52	Feasibility of Intraprostatic Prostate Cancer Imaging with FCH-PET/CT for Preoperative Planning of Image-Guided HDR Brachytherapy. Brachytherapy, 2019, 18, S72.	0.5	0
53	Sci-Thur PM: Imaging - 05: Calibration of a SPECT/CT camera for quantitative SPECT with 99m Tc. Medical Physics, 2014, 41, 4-4.	3.0	0
54	GLUT1 expression in high-risk prostate cancer: Correlation with 18F-FDG-PET/CT and clinical outcome.. Journal of Clinical Oncology, 2020, 38, 291-291.	1.6	0